When mice received treatment with the anti-Grem1 therapy prior to inoculation with 5TGM1 tumor cells, an even greater reduction in tumor burden of 81.2% was observed (p = 0.0496; median BLI; IgG control antibody, 2.44 × 107 photons/sec (interquartile range: 1.91 × 106–1.91 × 108) vs. anti-Grem1 antibody, 2.99 × 106 photons/sec (interquartile range: 4.95 × 105–3.47 × 107) (Figure 5C). This evidence concerns the gene GREM1 and neoplasm.